MARATTO

article · Journal of Arrhythmia

Trends and Disparities in Mortality due to Pulmonary Embolism Among Adults With Atrial Fibrillation From 1999 to 2020: Insights From the <scp>CDC</scp> <scp>WONDER</scp> Database

2026Open accessUniversity of Khartoum

Abstract

Background: Pulmonary embolism (PE) remains a major cause of cardiovascular mortality, and atrial fibrillation (AF) significantly worsens its outcomes. However, long-term trends and disparities in PE mortality among patients with AF remain poorly characterized. Methods: Using the CDC WONDER database (1999-2020), we identified adults with PE as the underlying cause of death and AF as a contributing cause using ICD-10 codes I26 and I48. Age-adjusted mortality rates (AAMRs) and annual percentage changes (APCs) were calculated via Joinpoint regression. Subgroup analyses were done based on the pre-, during, and post-COVID-19 pandemic era. Results: A total of 5499 deaths were recorded with PE and coexisting AF. Overall mortality remained stable from 1999 to 2009 (APC: -0.27; 95% CI: -2.12 to 1.60), then rose sharply from 2009 to 2020 (APC: 3.68; 95% CI: 2.29-5.10). Males had higher mortality (AAMR: 0.077) than females (0.065), with faster increases over time. Non-metropolitan areas showed greater mortality (AAMR: 0.082) than metropolitan areas (0.063), with steeper APCs (2.73% vs. 2.00%). Regionally, the Midwest (AAMR: 0.077) and South (0.073) bore the highest burden. States with the highest mortality included Vermont and Maryland. Most deaths occurred in inpatient settings (55.7%), followed by nursing homes (15.8%) and decedents' homes (14.5%). Notably, states with the lowest AAMRs were New York, Louisiana, and Florida. Conclusions: Mortality due to PE with AF as a contributor has increased significantly since 2009, with marked sex, regional, and urban-rural disparities. These findings underscore the growing public health burden and the need for targeted regional responses.

Research topics

  • Atrial Fibrillation Management and Outcomes
  • Venous Thromboembolism Diagnosis and Management
  • COVID-19 Clinical Research Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1002/joa3.70403

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.